Re-examination Study For General Drug Use to Assess the Safety and Efficacy Profile of EMEND in Usual Practice.

Trial Profile

Re-examination Study For General Drug Use to Assess the Safety and Efficacy Profile of EMEND in Usual Practice.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jun 2014

At a glance

  • Drugs Aprepitant (Primary)
  • Indications Nausea and vomiting
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 04 Oct 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
    • 22 Dec 2011 Actual patient number is 3482 according to ClinicalTrials.gov.
    • 22 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top